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Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S235chimerism, and the engraftment percent were statistically
signiﬁcant. No other statistical signiﬁcance was seen be-
tween the two groups with respect to age, HLA match, cell
dose, aGVHD, or TBI or other conditioning. In conclusion,
addition of Thiotepa to conditioning regimen dramatically
changes transplant outcomes of pediatric non malignancy
patients undergoing cord blood transplantation.362
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Group Variables.
Variable African American (31)
Median Range
Age 4.0 0.2- 20.6
TNC/Kg8 0.54 0.05- 2.75
MNC/Kg8 0.44 0.04- 2.55
CD34/Kg6 0.60 0.02- 7.6
N[ %
HLA 3/6, 4/6, 5/6, 6/6 4, 19, 6, 2 13, 61, 19, 7
Malignancy: Non-Malignancy 21, 10 67.7, 32.3
TBI: No TBI 24, 7 77.4, 22.6We retrospectively evaluated all CBT to see if there is a cor-
relation between patient ethnicity & transplant outcomes.
Between 1/1995 & 1/2011 we performed 145 CBT for the
treatment of malignant (95), non-malignant (50) conditions.
Conditioning regimen: TBI + VP16 + Cy (79); TBI + TT + VP16 +
Cy (16); Bu  Cy  FLUD (31); Cy  TT or VP16 (12); other
combinations (20).
Malignancies: ALL (47), AML (29), other (19); Pt status: PR
(7), CR1 (39), CR2 (42), CR3 (7).
Non-malignancies: Immunodeﬁciency (22); BM failure (10);
Metabolic (6); Histiocytic (6); Hemoglobinopathy (6).
Cohort was 65 F, 80 M; median age 3.8 yr (0.1 - 20.6), wt 15.5
kg (3.0 - 73.0).
Ethnicity: Caucasian (52), Hispanic (44), African American
(31), Asian (13), Mid Eastern (5).
HLA match: 6/6 (15), 5/6 (38), 4/6 (83), 3/6 (9).
Median cell dose/Kg: 0.64
ˇ
8 TNC, 0.56
ˇ
8 MNC & 0.70
ˇ
6 CD34.
GvHD prophylaxis: MTX + ATG + CSA/FK506  PRED (92);
MMF + ATG + CSA (16); CSA/FK506 + ATG  PRED (37).
Statistical analyses were done using Fisher’s Exact and log-
rank tests, column stats, and T- test. Signiﬁcance was deter-
mined at p-value of 0.05.
Overall Outcomes: ANC>500 cells/mL was achieved in 70.3%
of pts at 23 days (1 - 60); 66.2% achieved PLT count of
>20,000 at 42 days (14 - 100); and 64.8% achieved >95%All Others (114) P-value
Median Range
3.6 0.1- 17.4 0.11
0.68 0.12- 4.27 0.19
0.57 0.08- 3.84 0.23
0.80 0.02- 8.7 0.80
N[ %
5, 64, 32, 13 4, 56, 28, 11 0.18
74, 40 64.9, 35.1 0.83
71, 43 62.3, 37.7 0.14
Table 2
Group Outcomes.
Outcomes African American (31) All Others (114) P-value
Median R¼ Median R¼
Days to ANC 28 1- 51 23 15- 60 0.31
Days to PLT Engraft 45 25-81 42 14- 105 0.93
Days to Chimerism 28 19- 97 29 13- 100 0.67
N[ % N[ %
Alive, Died 17, 14 54.8, 45.2 67, 47 58.8, 41.2 0.69
Relapse 1 of 31 4.8 16 of 64 21.6 0.11
aGVHD 11 35.5 55 48.2 0.23
cGVHD 2 6.4 6 5.3 0.68
ANC Engraft 20 64.5 82 71.9 0.51
PLT Engraft 17 54.8 79 69.3 0.14
Chimerism >95% 15 48.4 79 69.3 0.031
TRM 12 38.7 20 17.5 0.012
Graph 1: K-M Survival.
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(58%) are survivors. EFS > 1, 3 & 5 yr was 50%, 41% & 37%
respectively, OS was 60%, 48% & 43%. 34 pts (23%) are event
free for > 10 yr. Median follow up was 2.6 yr (1.2 - 16.4 yr).
Grade II- IV acute GVHD was seen in 66 pts (46%), chronic
GVHD in 8 (6%).
Conclusion: Children of African American ethnicity had
statistically signiﬁcant increased Transplant Related Mortal-
ity and showed poor chimerism compared to other groups.
There was no other statistical signiﬁcance between the two
groups with respect to age, diagnosis, HLA match, cell dose,
conditioning, survival, relapse, engraftment or GVHD. Also,
there was no difference in transplant outcomes of the other
individual ethnic groups.363
Allogeneic Transplantation for MDS/AML Patients with
Germline GATA2 Mutations
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Adolescent Medicine, Mayo Clinic, Rochester, MN; 3 Laboratory
Med/Pathology and Medicine, Mayo Clinic, Rochester, MNBackground: Haploinsufﬁciency of GATA2 results in familial
immunodeﬁciency and MDS/ AML. We present our experi-
ence with allogeneic stem cell transplant (HCT) for a family
with germline GATA2 mutations.
Methods: After due IRB approval, the myeloid neoplasms
data base at the Mayo Clinic, was queried for patients with
germline GATA2 mutations. A single family with 9 affected
members was identiﬁed. Clinical and laboratory data were
retrospectively abstracted.
Results: All family members had a c1339A>C, pS447R
germline GATA2 mutation (ﬁgure one). Unlike most other
disease causing GATA2 mutations this mutation occurred in
the non-zinc ﬁnger domain. All 9 affected members have
developed MDS/AML, with 3 having successfully undergone
allo-HCT.
The proband presented with AML-MRC and +8. He had
extensive HPV papillomas and a family history of MDS. He
received standard induction chemotherapy and developed
profound marrow aplasia and absidia sinusitis. He under-
went a reduced intensity conditioning 9/10 HLA-DQ MUD
allo HCT. The transplant was complicated by CMV reac-
tivation and acute grade 1 GI GVHD. His day 100 bone
marrow biopsy has shown 100% donor chimerisms with no
residual disease.
Patient No.2 was diagnosed to have MDS-RCMD. She
underwent a myeloablative 10/10 HLA MUD transplant. She
developed acute grade 1 Skin GVHD. Day 30 testing
